Seeking Alpha

Wedbush takes a shine to Idenix Pharmaceuticals (IDIX +3.5%), ringing up an upgrade to...

Wedbush takes a shine to Idenix Pharmaceuticals (IDIX +3.5%), ringing up an upgrade to Outperform from Neutral to go along with a $5 price target hike to $11. Analysts with the firm tie the new rating to the "heightened premium" they see big-pharma placing on the nucleotide class of drugs following positive data released on Pharmasset’s (VRUS +2.3%) PSI-7977 treatment.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|